Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors
- 5 December 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 25 (3), 227-235
- https://doi.org/10.1007/s10637-006-9027-2
Abstract
Indibulin is a synthetic small molecule which antitumor activity is based upon destabilization of microtubules. The primary study objectives were to determine the impact of fasted and fed condition on pharmacokinetic parameters, as well as the maximum tolerated dose of the oral drinking solution of indibulin administered once daily for 14 days every 3 weeks in patients with solid tumors. In the pilot food effect part, patients received a single dose of 20 mg indibulin on day-8 and -4, fasted or fed, in a randomized crossover design. In the dose-escalation part, patients received a single dose of indibulin on day-4. Three dose levels were evaluated: 20, 40 and 80 mg. After a washout period, patients received indibulin once daily for 14 days every 3 weeks (multiple dose part). Blood samples were collected in the pilot food effect- and in the dose escalation study. A total of 14 patients entered, of which 6 completed the food effect study. The ratio of indibulin (fed/fasted) in the food effect study for AUC0-72 was estimated as 1.24 (P=0.082, 95%CI 0.96–1.41) and C max ratio was 0.89 (P=0.54, 95%CI 0.55–1.44). Interpatient variability was high. Higher peak plasma concentrations were reached under fasting conditions which was undesired regarding tolerability. Therefore the dose escalation study was continued under fed conditions. Dose limiting toxicities, nausea and vomiting, appeared to be related to the increased volume of the solvent lactic acid. This study is continued, evaluating indibulin administered as capsules on the recommended dose level of 60 mg daily for 14 days.Keywords
This publication has 11 references indexed in Scilit:
- Mechanism of Action of Antitumor Drugs that Interact with Microtubules and TubulinCurrent Medicinal Chemistry - Anti-Cancer Agents, 2012
- Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometryRapid Communications in Mass Spectrometry, 2004
- Past and future of the mitotic spindle as an oncology targetCurrent Opinion in Pharmacology, 2001
- D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity.2001
- Chemotherapeutic neuropathyCurrent Opinion in Neurology, 1999
- Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell DeathJournal of Clinical Oncology, 1999
- Role of taxanes in lung-cancer chemotherapy.Cancer Investigation, 1998
- THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTSAnnual Review of Medicine, 1997
- Motor neuropathy due to docetaxel and paclitaxelNeurology, 1996
- Neurotoxicity of antineoplastic agentsCritical Reviews in Oncology/Hematology, 1993